Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novabay Pharmaceuticals (NY: NBY )

0.0770 +0.0045 (+6.21%)
Official Closing Price Updated: 8:00 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,571,117
Open 0.0703
Bid (Size) 0.0756 (71)
Ask (Size) 0.0824 (5)
Prev. Close 0.0725
Today's Range 0.0680 - 0.0791
52wk Range 0.0650 - 1.520
Shares Outstanding 30,098,150
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
From NovaBay Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-60.43%
-60.43%
1 Month
-40.26%
-40.26%
3 Month
-52.17%
-52.17%
6 Month
-78.30%
-78.30%
1 Year
-94.54%
-94.54%

More News

Read More
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
Recap: NovaBay Pharmaceuticals Q3 Earnings
Via Benzinga
NBY Stock Earnings: NovaBay Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For March 26, 2024
Via Benzinga
Earnings Preview For NovaBay Pharmaceuticals
Via Benzinga
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
Via ACCESSWIRE
NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.